Topic:

M&A

Latest Headlines

Latest Headlines

GlaxoSmithKline punts its cancer R&D work in Big Pharma swap and shop

Novartis, GlaxoSmithKline and Eli Lilly have hammered out a pact to swap, sell and partner on a group of four different divisions, realigning the corporate and marketing landscape for each of the big three pharma players. 

Eli Lilly's Elanco snags Novartis' animal health unit in $5.4B deal

Novartis has agreed to sell its veterinary products business to Eli Lilly, whose Elanco unit is among the biggest players in animal health, for about $5.4 billion

GlaxoSmithKline and Novartis, starring players in a Big Pharma deal bonanza

While the chattering classes were chattering about a potential Pfizer-AstraZeneca merger yesterday, three other drug giants were putting the finishing touches on a big announcement. Novartis, whose strategic review has been making headlines for almost a year, agreed to swap some assets with GlaxoSmithKline and sell its animal health business to Eli Lilly.

Analysts brace for a brawl as Valeant moves ahead with $46B Allergan bid

Activist investor William Ackman has allied himself with biopharma raider Michael Pearson at Valeant to buy out Allergan, the maker of Botox, which has been actively hunting down its own buyouts, according to a report Monday evening from The Wall Street Journal.

Quest buys Summit Health as it aims to restore growth

Quest Diagnostics' revenues fell in the fourth quarter of 2013--a direct violation of its 5-point strategy including "restore growth"--but the company thinks its acquisition of prevention and wellness services outfit Summit Health will help fix those problems.

Aastrom surges after acquiring Sanofi's cell therapies

A little more than a year after reorganizing the company and slashing staff in the wake of a Phase III failure, Ann Arbor, MI-based Aastrom Biosciences has acquired Sanofi's cell therapy and regenerative medicine business for the low, low purchase price of $6.5 million--$4 million payable in cash and $2.5 million in a promissory note.

Bulk up or slim down? Maybe both: Pfizer said to weigh a $100B deal for AstraZeneca

We thought Pfizer was on a diet. After all, CEO Ian Read has garnered investor acclaim for his unit sales and spinoffs, and more of that action is expected. But the U.S.-based drug behemoth reportedly made a $100 billion-plus merger pitch to its struggling rival AstraZeneca. That would be quite a deal to digest.

OPKO buying Israeli inhaler outfit Inspiro Medical

OPKO Health said it has reached an agreement to acquire Inspiro Medical, an Israel-based company that makes an inhaler for the treatment of respiratory diseases.

Say what? Pfizer's $101B buyout pitch to AstraZeneca sparks a megadebate

Pfizer has reportedly made overtures offering to buy the struggling pharma giant AstraZeneca for $101 billion, setting the stage for what could be the first megamatchup in pharma land in years.

Novartis near to wrapping up $1.7B sale of part-owned patchmaker LTS Lohmann

It's been almost a yearlong contest, but a deal for patchmaker LTS Lohmann appears to be nearing the finish line. The private equity firm Nordic Capital is likely to beat out competitor Wendel for the deal, Bloomberg says, at a price of about $1.7 billion.